DK1520175T3 - Oncolytiske vira som midler til fænotypebestemmelse af neoplasmer - Google Patents

Oncolytiske vira som midler til fænotypebestemmelse af neoplasmer

Info

Publication number
DK1520175T3
DK1520175T3 DK03737795T DK03737795T DK1520175T3 DK 1520175 T3 DK1520175 T3 DK 1520175T3 DK 03737795 T DK03737795 T DK 03737795T DK 03737795 T DK03737795 T DK 03737795T DK 1520175 T3 DK1520175 T3 DK 1520175T3
Authority
DK
Denmark
Prior art keywords
neoplasms
agents
oncolytic viruses
phenotype determination
phenotype
Prior art date
Application number
DK03737795T
Other languages
English (en)
Inventor
Bradley G Thompson
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of DK1520175T3 publication Critical patent/DK1520175T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
DK03737795T 2002-06-28 2003-06-25 Oncolytiske vira som midler til fænotypebestemmelse af neoplasmer DK1520175T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39203102P 2002-06-28 2002-06-28
US44318803P 2003-01-29 2003-01-29
PCT/CA2003/000951 WO2004003562A2 (en) 2002-06-28 2003-06-25 Oncolytic viruses as phenotyping agents for neoplasms

Publications (1)

Publication Number Publication Date
DK1520175T3 true DK1520175T3 (da) 2008-02-11

Family

ID=30003222

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07021569.4T DK1890151T3 (da) 2002-06-28 2003-06-25 Onkolytiske vira som midler til fænotypebestemmelse for neoplasmer
DK03737795T DK1520175T3 (da) 2002-06-28 2003-06-25 Oncolytiske vira som midler til fænotypebestemmelse af neoplasmer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07021569.4T DK1890151T3 (da) 2002-06-28 2003-06-25 Onkolytiske vira som midler til fænotypebestemmelse for neoplasmer

Country Status (20)

Country Link
US (3) US7306902B2 (da)
EP (2) EP1890151B1 (da)
JP (1) JP2005531306A (da)
CN (1) CN1666105B (da)
AR (1) AR039768A1 (da)
AT (2) ATE377754T1 (da)
AU (2) AU2003245760B2 (da)
BR (1) BR0311983A (da)
CA (1) CA2487824C (da)
DE (1) DE60317331T2 (da)
DK (2) DK1890151T3 (da)
ES (2) ES2385845T3 (da)
HK (2) HK1069877A1 (da)
IL (2) IL165498A0 (da)
MX (1) MXPA04012414A (da)
NZ (1) NZ537116A (da)
PT (1) PT1890151E (da)
SI (1) SI1890151T1 (da)
TW (3) TWI402345B (da)
WO (1) WO2004003562A2 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
WO2004009763A2 (en) 2002-07-24 2004-01-29 Arizona Board Of Regents Use of vaccinia virus deleted for the e3l gene as a vaccine vector
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2005007824A2 (en) * 2003-07-08 2005-01-27 Arizona Board Of Regents Mutants of vaccinia virus as oncolytic agents
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
CA2617600A1 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US20090311664A1 (en) * 2005-12-22 2009-12-17 Yuman Fong Method for Detection of Cancer Cells Using Virus
ES2551306T3 (es) * 2006-02-13 2015-11-17 Oncolytics Biotech Inc. Uso de inmunosupresión local de baja dosis para potenciar una terapia viral oncolítica
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
WO2009143468A1 (en) * 2008-05-22 2009-11-26 Uti Limited Partnership Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy
WO2009143610A1 (en) * 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
MX2010012857A (es) * 2008-05-27 2010-12-20 Oncolytics Biotech Inc Supresion de produccion de citoquina proinflamatoria durante la terapia de reovirus oncolitico.
US8481297B2 (en) * 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
WO2013052915A2 (en) 2011-10-05 2013-04-11 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
WO2014018113A1 (en) 2012-07-24 2014-01-30 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
EP2890720B1 (en) 2012-08-30 2019-07-17 The General Hospital Corporation Compositions and methods for treating cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
WO2015089280A1 (en) * 2013-12-11 2015-06-18 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
PL3207130T3 (pl) 2014-10-14 2020-02-28 Halozyme, Inc. Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
CA2977660A1 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CA2982896A1 (en) 2015-04-17 2016-10-20 Memorial Sloan Kettering Cancer Center Use of modified vaccinia ankara virus (mva) or mva with a deletion of virulence factor e8 as immunotherapeutic agent against solid tumors
MX2018010204A (es) 2016-02-25 2019-05-06 Memorial Sloan Kettering Cancer Center Virus de la vaccinia atenuada competentes para replicacion con la supresion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer.
MX2018010231A (es) 2016-02-25 2019-06-06 Memorial Sloan Kettering Cancer Center Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos.
MA43552A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de cd80 et leurs utilisations
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
WO2017205674A1 (en) 2016-05-25 2017-11-30 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic vaccinia virus mutants and using same for cancer treatment
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CA3032120A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
CA3037573A1 (en) * 2016-09-27 2018-04-05 Sator Therapeutics LLC Optimized oncolytic viruses and uses thereof
EP3872180A1 (en) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
CA3052473A1 (en) 2017-02-09 2018-08-16 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and compositions and methods thereof
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
FI3596116T3 (fi) 2017-03-16 2023-11-09 Alpine Immune Sciences Inc Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
NZ756395A (en) 2017-03-16 2024-01-26 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
KR20200085777A (ko) 2017-10-18 2020-07-15 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 icos 리간드 면역조절 단백질 및 관련 조성물 및 방법
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
CA3177467A1 (en) 2018-06-04 2019-12-12 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
EP3844276A2 (en) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
AU2019377141A1 (en) 2018-11-06 2021-05-20 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
CN113891934A (zh) 2018-11-21 2022-01-04 因达普塔治疗公司 扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法
AU2019389151A1 (en) 2018-11-30 2021-06-10 Alpine Immune Sciences, Inc. CD86 variant immunomodulatory proteins and uses thereof
CA3131017A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US20230190801A1 (en) 2020-04-22 2023-06-22 Indapta Therapeutics, Inc. Natural killer (nk) cell compositions and methods for generating same
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5670330A (en) * 1992-09-29 1997-09-23 Mcgill University Anti-tumor agent assay using PKR
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
DE69417734T2 (de) 1993-02-16 1999-10-07 Onyx Pharma Inc Cytopathische viren zur therapie und prophylaxe der neoplasie
DE69435155D1 (de) 1993-04-30 2008-12-04 Wellstat Biologics Corp Zusuammensetzungen zur Behandlung von Krebs mittels Viren
JPH09506866A (ja) 1993-12-14 1997-07-08 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 医薬として活性のある物質の免疫療法のための放出制御
WO1995032300A1 (en) 1994-05-23 1995-11-30 University Of Medicine & Dentistry Of New Jersey Selective biological destruction of tumor cells
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5840502A (en) 1994-08-31 1998-11-24 Activated Cell Therapy, Inc. Methods for enriching specific cell-types by density gradient centrifugation
US6777177B1 (en) * 1997-10-10 2004-08-17 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
CA2508238C (en) 1997-08-13 2008-01-15 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
US6475481B2 (en) 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
WO1999045783A1 (en) 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
DE69929986T2 (de) 1998-08-31 2006-10-19 Ambrus, Julian L. Verfahren zur entfernung von hiv und anderen viren aus blut
EP1390046A4 (en) 1999-04-15 2005-04-20 Wellstat Biologics Corp TREATMENT OF NEOPLASMS WITH VIRUSES
DE19934788B4 (de) * 1999-07-27 2004-05-27 T-Mobile Deutschland Gmbh Verfahren zur automatischen Anpassung von Daten an die Fähigkeiten einer Nutzer-Software
ES2260057T3 (es) 1999-09-17 2006-11-01 Wellstat Biologics Corporation Virus oncolitico.
EP1227828A1 (en) 1999-11-12 2002-08-07 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
AR028040A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US20020037543A1 (en) 2000-06-26 2002-03-28 Atkins Harold L. Purging of cells using viruses
WO2002004596A2 (en) 2000-07-07 2002-01-17 President And Fellows Of Harvard College Diagnosing and treating cancer cells using mutant viruses
BR0115235A (pt) 2000-11-09 2003-10-14 Oncolytics Biotech Inc Métodos de determinar a suscetibilidade de uma célula à infecção por reovìrus, e, uso de uma composição compreendendo um ou mais reovìrus
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways

Also Published As

Publication number Publication date
TW201005097A (en) 2010-02-01
EP1890151A1 (en) 2008-02-20
ATE377754T1 (de) 2007-11-15
EP1520175B1 (en) 2007-11-07
ES2292981T3 (es) 2008-03-16
US20040029112A1 (en) 2004-02-12
TWI334444B (en) 2010-12-11
TW200940709A (en) 2009-10-01
TW200401032A (en) 2004-01-16
EP1520175A2 (en) 2005-04-06
AU2008207579B2 (en) 2011-10-20
DK1890151T3 (da) 2012-06-18
US20100105122A1 (en) 2010-04-29
SI1890151T1 (sl) 2012-08-31
AU2008207579A1 (en) 2008-09-18
NZ537116A (en) 2008-04-30
WO2004003562A3 (en) 2004-05-06
DE60317331D1 (de) 2007-12-20
IL220139A (en) 2013-03-24
CN1666105A (zh) 2005-09-07
BR0311983A (pt) 2005-04-26
US7306902B2 (en) 2007-12-11
ES2385845T3 (es) 2012-08-01
AR039768A1 (es) 2005-03-09
CA2487824A1 (en) 2004-01-08
DE60317331T2 (de) 2008-08-21
PT1890151E (pt) 2012-05-25
US20080014577A1 (en) 2008-01-17
TWI402345B (zh) 2013-07-21
ATE555388T1 (de) 2012-05-15
US8222036B2 (en) 2012-07-17
IL220139A0 (en) 2012-07-31
WO2004003562A2 (en) 2004-01-08
MXPA04012414A (es) 2005-04-19
HK1069877A1 (en) 2005-06-03
JP2005531306A (ja) 2005-10-20
HK1112509A1 (en) 2008-09-05
AU2003245760A1 (en) 2004-01-19
TWI327167B (en) 2010-07-11
EP1890151B1 (en) 2012-04-25
CA2487824C (en) 2013-08-20
AU2003245760B2 (en) 2008-07-03
CN1666105B (zh) 2015-11-25
IL165498A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
DK1520175T3 (da) Oncolytiske vira som midler til fænotypebestemmelse af neoplasmer
ATE506104T1 (de) Hepatitis-c-virus-hemmer
DK1730110T3 (da) Svovlforbindelser som inhibitorer af hepatitis C-virus NS3-serinprotease
NO20043642L (no) Heterocykiske tripeptider som hepatitt C inhibitorer
IS8476A (is) Lifrarbólgu C-veirutálmar
IS8475A (is) Lifrarbólgu C-veirutálmar
DK3395339T3 (da) Hurtigt opløsende formulering af cinacalcet-hcl
DK1562589T3 (da) Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
DK1402075T3 (da) Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
IS8323A (is) Ný amínóbensófenónefnasambönd
NO20023283D0 (no) Flammestopper
DK1802579T3 (da) Derivater af 3-arylaminopyridin
IS7607A (is) Ný útskipt indól
DK1504126T3 (da) Fremgangsmåde til regulering af genekspression
DK2060570T3 (da) Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater
DK1542977T3 (da) 2,5-dioxoimidazolidin-4-ylacetamider og analoger som inhibitorer af metalloproteinase MMP12
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DK1997512T3 (da) Fremgangsmåder til behandling af TWEAK-relaterede tilstande
DE602004025775D1 (de) Innengekühltes strömungsleitendes Komponent
DK1401828T3 (da) N-Formylhydroxylaminforbindelser som inhibitorer af PDF
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
ATE398450T1 (de) Derivate von aryl-chinazolin/aryl-2amino-phenyl- methanon zurförderung der freisetzung von parathormon
DK1773787T3 (da) Fremgangsmåde til fremstilling af 3-phenyl(thio)uraciler og -dithiouraciler
DE602004012448D1 (de) Morpholinylhaltige benzimidazole als inhibitoren der replikation von respiratory syncytial virus